

Title (en)

DRUG FOR CANCER THERAPY CHARACTERIZED BY ADMINISTERING COMBINATION BETWEEN AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR

Title (de)

MEDIKAMENT ZUR BEHANDLUNG VON KREBS DURCH VERABREICHUNG EINER KOMBINATION AUS EINEM AXL-HEMMER UND IMMUNE-CHECKPOINT-INHIBITOR

Title (fr)

MÉDICAMENT POUR LE TRAITEMENT DU CANCER CARACTÉRISÉ PAR L'ADMINISTRATION D'UNE ASSOCIATION D'UN INHIBITEUR DE L'AXL ET D'UN INHIBITEUR DE POINT DE CONTRÔLE IMMUNITAIRE

Publication

**EP 3421039 A1 20190102 (EN)**

Application

**EP 17756670 A 20170224**

Priority

- JP 2016035206 A 20160226
- JP 2017007219 W 20170224

Abstract (en)

The present invention addresses the problem of discovering and providing an effective cancer therapy by means of a drug. Provided is a drug for cancer therapy characterized by administering a combination between: a compound represented by a general formula (I) (wherein, all symbols are as described in the description), a salt thereof, a solvate thereof, an N-oxide thereof, or an Ax1 inhibitor as a prodrug of those; and an immune checkpoint inhibitor (e.g., anti-PD-1 antibody, etc.). The combination according to the present invention exerts a strong anti-tumor effect, and thereby is useful in cancer therapy.

IPC 8 full level

**A61K 31/4709** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07K 16/18** (2006.01)

CPC (source: EP US)

**A61K 31/4709** (2013.01 - EP US); **A61K 31/519** (2013.01 - EP US); **A61K 39/395** (2013.01 - EP US); **A61K 45/00** (2013.01 - EP US);  
**A61P 35/00** (2017.12 - EP US); **C07K 16/18** (2013.01 - EP US); **C07K 16/2827** (2013.01 - US)

Cited by

EP3673907A4

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

**EP 3421039 A1 20190102; EP 3421039 A4 20190102; EP 3421039 B1 20211006;** ES 2896079 T3 20220223; JP 6885390 B2 20210616;  
JP WO2017146236 A1 20181220; US 2019099413 A1 20190404; WO 2017146236 A1 20170831

DOCDB simple family (application)

**EP 17756670 A 20170224;** ES 17756670 T 20170224; JP 2017007219 W 20170224; JP 2018501812 A 20170224;  
US 201716079823 A 20170224